Inovio Pharmaceuticals, Inc. (INO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Inovio Pharmaceuticals reported revenue of $65,343, down 70.0% from $217,756 the year before. Net income was -$84.9M (a -130000.0% net margin), or -$1.81 per diluted share. Operating margin was -132871.3%. Operating activities generated -$88.6M of cash, leaving -$88.9M of free cash flow. At fiscal year end, Inovio Pharmaceuticals held $74.3M in total assets against $50.2M in total liabilities, including $44.3M of cash and equivalents.
Open the full interactive Inovio Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Inovio Pharmaceuticals Key Stats
| Share Price | $1.00 |
|---|---|
| Market Cap | $81.6M |
| Revenue YoY Growth | -70.0% |
| 52-Week Range | $0.66 – $2.60 |
| Shares Outstanding | 81.6 million (basic, 2026 Q2) |
Inovio Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $1.8M | $10.3M | $832,010 | $217,756 | $65,343 |
| Operating Income | -$124.1M | -$301.2M | -$267.6M | -$143.9M | -$112.4M | -$86.8M |
| Pre-Tax Income | -$162.9M | -$303.2M | -$277.7M | -$135.1M | -$107.3M | -$84.9M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$166.4M | -$303.7M | -$279.8M | -$135.1M | -$107.3M | -$84.9M |
| Diluted EPS | -$1.68 | -$17.40 | -$14.04 | -$6.09 | -$3.95 | -$1.81 |
Inovio Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$45.5M | $3.8M | -$19.7M | -$6.0M |
| Diluted EPS | -$0.87 | $0.08 | -$0.28 | -$0.07 |
Inovio Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $250.7M | $71.1M | $46.3M | $14.3M | $65.8M | $44.3M |
| Current Assets | $471.2M | $448.4M | $315.2M | $153.1M | $97.8M | $61.1M |
| Total Assets | $539.8M | $495.9M | $348.5M | $171.0M | $113.2M | $74.3M |
| Current Liabilities | $41.7M | $65.7M | $96.9M | $42.6M | $35.3M | $43.7M |
| Total Liabilities | $78.6M | $96.3M | $126.2M | $53.6M | $44.7M | $50.2M |
| Shareholders' Equity | $461.1M | $399.7M | $222.4M | $117.3M | $68.5M | $24.1M |
Inovio Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$178.0M | -$215.7M | -$216.2M | -$124.4M | -$104.1M | -$88.6M |
| Cash From Investing | -$58.8M | -$175.3M | $109.6M | $87.4M | $104.1M | $14.0M |
| Cash From Financing | $465.3M | $211.5M | $81.8M | $5.0M | $51.5M | $53.1M |
| Free Cash Flow | -$179.5M | -$216.9M | -$217.2M | -$124.7M | -$104.6M | -$88.9M |
Figures from Inovio Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Inovio Pharmaceuticals financials page for every line item.
Inovio Pharmaceuticals Company Profile
| Ticker | INO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Plymouth Meeting, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001055726 |
Frequently Asked Questions
What was Inovio Pharmaceuticals' revenue in fiscal 2025?
Inovio Pharmaceuticals (INO) reported revenue of $65,343 for fiscal 2025.
What is Inovio Pharmaceuticals' annual revenue history?
Inovio Pharmaceuticals' annual revenue by fiscal year: 2020: $7.4M; 2021: $1.8M; 2022: $10.3M; 2023: $832,010; 2024: $217,756; 2025: $65,343.
What was Inovio Pharmaceuticals' net income in fiscal 2025?
Inovio Pharmaceuticals reported net income of -$84.9M for fiscal 2025.
What was Inovio Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Inovio Pharmaceuticals' diluted EPS was -$1.81 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Inovio Pharmaceuticals generate in fiscal 2025?
Inovio Pharmaceuticals generated -$88.9M of free cash flow in fiscal 2025.
What was Inovio Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Inovio Pharmaceuticals reported revenue of $0.
How many shares of Inovio Pharmaceuticals are outstanding?
Inovio Pharmaceuticals reported a weighted average of 81.6 million basic shares outstanding in 2026 Q2.
What is Inovio Pharmaceuticals' market cap?
Based on its latest closing price, Inovio Pharmaceuticals (INO) has a market capitalization of about $81.6M.
When does Inovio Pharmaceuticals' fiscal year end?
Inovio Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Inovio Pharmaceuticals headquartered?
Inovio Pharmaceuticals lists its business address in Plymouth Meeting, Pennsylvania in its SEC filings.